Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.36 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ADA | P00813 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9912327 | 1.00 | ADORA3 (0.37) | ADORA3ADORA2AADORA1ADORA2BTMPRSS2 | |
| SCHEMBL13691382 | 0.90 | ADORA3 (0.39) | ADORA3ADORA2AADORA1ADORA2BTMPRSS2 | |
| SCHEMBL2722884 | 0.84 | ADORA2A (0.46) | ADORA3ADORA2AADORA1ADORA2BTMPRSS2 | |
| SCHEMBL646134 | 0.84 | ADORA2A (0.46) | ADORA3ADORA2AADORA1ADORA2BTMPRSS2 | |
| SCHEMBL13519758 | 0.84 | ADORA2A (0.46) | ADORA3ADORA2AADORA1ADORA2BTMPRSS2 | |
| SCHEMBL17117149 | 0.84 | ADORA2A (0.46) | ADORA3ADORA2AADORA1ADORA2BTMPRSS2 | |
| SCHEMBL17109576 | 0.84 | ADORA2A (0.46) | ADORA3ADORA2AADORA1ADORA2BTMPRSS2 | |
| SCHEMBL19644967 | 0.84 | ADORA2A (0.46) | ADORA3ADORA2AADORA1ADORA2BTMPRSS2 | |
| SCHEMBL13695331 | 0.84 | ADORA2A (0.46) | ADORA3ADORA2AADORA1ADORA2BTMPRSS2 | |
| SCHEMBL10100358 | 0.82 | ADORA2A (0.37) | ADORA3ADORA2AADORA1ADORA2BADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | EIF2AK2, ZC3HAV1, MAVS | ADORA3 2842/4885ADORA2A 3132/4885ADORA1 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.